Back to MRKMERCK (MRK)View full pipeline
carboplatin AUC of 6, paclitaxel 175 mg/m2, and pembrolizumab 200 mg, i.v. on day 1, every 21 days for 3 cycles
Phase 2Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
0 competitors in Squamous Cell Carcinoma of Larynx
View Full LandscapeDrug Information
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Drug Science
Mechanism of action & safety profile
Related Pipeline
MK-8748Phase 3
Diabetic Retinopathy
alendronate with cholecalciferolPhase 3
Osteoporosis
Simvastatin 20 mg dailyPhase 3
Cardiovascular Disease
EpinephrinePhase 3
Malignant Neoplasms of Male Genital Organs
9 valent human papillomavirus vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, 58)Phase 3
HPV Positive Oropharyngeal Squamous Cell Carcinoma
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts